Home » Newsletters » BioWorld Asia

BioWorld Asia

May 14, 2003

View Archived Issues

Longtime U.S. Investor Adds Perspective To GLSV Venture

MUNICH, Germany - Is this the worst bear market he's ever seen in biotechnology? (BioWorld International) Read More

QLT, Xenova Suffer Setback As Pivotal Tariquidar Trial Stopped

Molecular Zipper Helps Bind Bacteria To Human Host Cells

European Ministers Review Plan To Implement Biotech Strategy

Acambis Benefits From U.S. Consolidation Of Contracts

UK Industry Riding Out Downturn, Surviving Till Sector Turns Around

Tel Aviv University Forms Fund To Push Commercial Potential

Vivalis Licenses Stem Cell Lines To Aventis For Vaccine Production

Axaron Cutback To Focus On Stroke Reflects German Sector

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.